Lung cancer
Conditions
Interventions
SABT combined with IMRT treatment group:Stereotactic brachyablation+intensity modulated radiation therapy
IMRT treatment group:Intensity modulated radiation therapy
Sponsors
Jintan First People's Hospital, Changzhou
Eligibility
Sex/Gender
All
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. For patients with peripheral non-small cell lung cancer who cannot be surgically resected or who cannot tolerate surgery due to underlying diseases or pathologically or cytologically confirmed by surgery, surgical resection should be decided by a multidisciplinary team. 2. Aged 60-80 years. 3. There are no contraindications to radiotherapy, and the expected survival is more than 6 months after radiotherapy. 4. ECOG score is 0-2. 5. Lung function test: forced expiratory volume in one second; FEV1>=1.2 L/s or >=50% expected value. 6. No previous history of other lung malignancies, and no chest radiotherapy for lung tumors. 7. Normal bone marrow function is as follows: White blood cell count >4x10^9 / L, hemoglobin >90g / L(without blood transfusion), neutrophil count >=2.0x10^9 / L, platelet count >=100x10^9 / L, normal serum creatinine or creatinine clearance >=60 mL / min, ALT and AST < 2.5 times the normal reference value. Bilirubin is within the normal range. 8. Normal coagulation function: PT 12 ~ 16s,INR 0.8 ~ 1.5,APTT24 ~ 36s,FIB2 ~ 4g/L; pre-transfusion examination: HIV and TP were negative (-). 9. No allergic history of lidocaine and other anesthetic drugs. 10. The patient indicated informed consent and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. A history of serious cardiovascular diseases, such as uncontrolled hypertension, unstable angina pectoris, congestive heart failure, acute myocardial infarction; Transmural myocardial infarction occurred within 6 months. 2. Patients with uncontrolled neuropathy (grade 2 or above) or psychosis. 3. A history of invasive malignant tumor within 3 years (skin cancer excluding non-malignant melanoma, carcinoma in situ of breast, cervix and oral cavity). 4. Patients with exacerbation of copd within 30 days prior to enrollment requiring hospitalization or who may not be able to tolerate the treatment of this study regimen. 5. Patients with acute bacterial or fungal infection requiring intravenous anti-infection treatment when enrolled. 6. Liver insufficiency resulting in jaundice or coagulation dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Short-term curative effect ; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of hemothorax;The incidence of pneumothorax;Long term survival analysis; | — |
Countries
China
Contacts
Public ContactXu Junma
Jintan First People's Hospital, Changzhou
Outcome results
None listed